Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rockland Immunochemicals Releases Host Cell Protein Antibodies

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
New host cell antibodies and custom assays improve bioprocessing workflow by detecting host cell protein contaminants.

Rockland Immunochemicals, Inc. has announced the release of Host Cell Protein (HCP) antibodies that detect high, medium and low molecular weight proteins.  Host Cell Proteins are process-related impurities derived from a host cell expression system that may be present in trace amounts in a final drug substance. HCP antibodies are used to detect impurities in biologically-based therapeutics. Assays are further developed using custom-manufactured process specific antibodies.

Rockland’s new HCP antibodies will be released and a standardized HCP immunoassay development process presented during the Well Characterized Biotechnology Pharmaceuticals (WCBP) Symposium in Washington, DC January 29-31. This United States Food and Drug Administration (FDA) co-sponsored symposium is the pre-eminent conference addressing the analytical development/regulatory control interface for biotechnology derived health intervention products.

The FDA requires that pharmaceutical and biotechnology companies producing therapeutic antibodies minimize HCP contamination to an acceptable level. Failure to identify and sufficiently remove contaminants early in drug development can result in reduced drug efficacy or adverse toxic or immunological reactions in patients.

ELISA, the most widely used assay for determining the presence of HCPs, uses a polyclonal antibody mixture raised against host cell proteins. The accepted workflow for evaluating the immunocoverage of HCP antibodies involves 2-D gel electrophoresis followed by Western blotting. Rockland now provides Bioprocessing researchers with antibodies and custom HCP assay development  services that streamlines and regulates this workflow.

At the WCBP Symposium, Rockland researchers will present data that shows an improved standardized immunoassay development process for HCP detection using 2D electrophoresis and western blotting. In collaboration with Bio-Rad, the PROTEAN® i12™ IEF System was used to develop the HCP antibodies and measure/calibrate assays. Detecting impurities often unseen by 1-D electrophoresis, this system delivers more complete insight into the immunocoverage of protein components of the host cell lysate. The newly developed Rockland antibodies have been fully evaluated using the 2-D electrophoresis workflow and  provide efficient immunocoverage of E.coli HCP.

“Rockland’s expertise in HCP antibodies and HCP assay development services has allowed Bio-Rad to affirm the value of optimized IEF separations in generating a robust 2D-electrophoresis based assay for evaluating anti-HCP antibodies, ” said Sricharan Bandhakavi, Senior Scientist at Bio-Rad Laboratories.

"Over the last decade, BioPharma has invested significant amounts of money to develop large molecule (antibody) drugs. As these drugs move forward in the approval process, reagents and assays used to analyze purity will increase in importance,” commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “With our well-developed antibody and assay technology, Rockland is well positioned to take advantage of this opportunity and set the standard for optimal quality of application."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rockland Awarded SBIR Funding
Company awarded grant to develop antibody-based point of care device for the diagnosis of sickle cell disease.
Tuesday, September 09, 2014
Rockland Immunochemicals Expands into 60,000 Square Foot Facility
Company expands laboratories to keep pace with growth.
Thursday, May 29, 2014
Rockland Immunochemicals Awarded Phase I SBIR Funding
SBIR grant to develop nanoprobes for in vivo imaging of cancer cells and tumors.
Tuesday, October 22, 2013
Rockland Immunochemicals Acquires Epi-Plus® Product Line
Rockland Immunochemicals, Inc. announced the acquisition of the Epi-Plus® antibody product line from 21st Century Biochemicals, Inc.
Tuesday, April 09, 2013
Rockland and LIMR Expand Licensing and Commercialization Relationship
Rockland will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.
Tuesday, October 30, 2012
Rockland Immunochemicals Awarded Phase II SBIR Funding
Company receives grant for 1 million dollars to develop Akt/mTOR signaling pharmacodynamics assay.
Tuesday, October 16, 2012
Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
Rockland will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies.
Monday, April 23, 2012
Rockland Immunochemicals and Emory University Sign Master Reagent Agreement
Rockland and Emory collaborate to develop novel antibodies and antibody based tools for cancer, cell signaling and chromatin research.
Friday, January 28, 2011
Rockland Immunochemicals Awarded Phase I Funding to Develop Generic Antibodies for the Treatment of Cancer
Rockland Immunochemicals Inc. have received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
Thursday, November 04, 2010
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!